中国中西医结合外科杂志
中國中西醫結閤外科雜誌
중국중서의결합외과잡지
CHINESE JOURNAL OF SURGERY OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2014年
3期
230-234
,共5页
肖宝强%刘晶晶%史振东%张晟
肖寶彊%劉晶晶%史振東%張晟
초보강%류정정%사진동%장성
紫杉类药%蒽环类药%三阴性乳腺癌%辅助化疗
紫杉類藥%蒽環類藥%三陰性乳腺癌%輔助化療
자삼류약%은배류약%삼음성유선암%보조화료
Taxanes%antracycline%triple-negative breast cancer%adjuvant chemotherapy
目的：比较紫杉类和蒽环类药物联合与单纯蒽环类药物治疗三阴性乳腺癌的疗效。方法：585例三阴性乳腺癌患者中，术后行紫杉联合蒽环类辅助化疗228例，蒽环类辅助化疗357例，分析其复发、转移和生存情况。结果：紫杉联合蒽环类组与蒽环类组患者复发率、转移率与死亡率分别为7.9%与13.2%、21.9%与35.9%、18.0%与28.6%（P＜0.05），与蒽环类方案相比，紫杉联合蒽环类方案延长了临床II、III期、非特殊型浸润性癌、淋巴结阳性患者的总生存期，提高了总生存率。结论：紫杉类与蒽环类药物联合辅助化疗，对于具有晚临床分期、非特殊型浸润性癌及淋巴结阳性特征的三阴性乳腺癌有显著的治疗效果。
目的：比較紫杉類和蒽環類藥物聯閤與單純蒽環類藥物治療三陰性乳腺癌的療效。方法：585例三陰性乳腺癌患者中，術後行紫杉聯閤蒽環類輔助化療228例，蒽環類輔助化療357例，分析其複髮、轉移和生存情況。結果：紫杉聯閤蒽環類組與蒽環類組患者複髮率、轉移率與死亡率分彆為7.9%與13.2%、21.9%與35.9%、18.0%與28.6%（P＜0.05），與蒽環類方案相比，紫杉聯閤蒽環類方案延長瞭臨床II、III期、非特殊型浸潤性癌、淋巴結暘性患者的總生存期，提高瞭總生存率。結論：紫杉類與蒽環類藥物聯閤輔助化療，對于具有晚臨床分期、非特殊型浸潤性癌及淋巴結暘性特徵的三陰性乳腺癌有顯著的治療效果。
목적：비교자삼류화은배류약물연합여단순은배류약물치료삼음성유선암적료효。방법：585례삼음성유선암환자중，술후행자삼연합은배류보조화료228례，은배류보조화료357례，분석기복발、전이화생존정황。결과：자삼연합은배류조여은배류조환자복발솔、전이솔여사망솔분별위7.9%여13.2%、21.9%여35.9%、18.0%여28.6%（P＜0.05），여은배류방안상비，자삼연합은배류방안연장료림상II、III기、비특수형침윤성암、림파결양성환자적총생존기，제고료총생존솔。결론：자삼류여은배류약물연합보조화료，대우구유만림상분기、비특수형침윤성암급림파결양성특정적삼음성유선암유현저적치료효과。
Objective To investigate the antitumor efficacy of taxanes and antracycline drugs in triple-nega-tive breast cancer. Methods Of 585 patients with histopathologically confirmed resectable triple-negative breast cancer, 228 patients received adjuvant chemotherapy with taxanes plus antracycline, and the other 357 pa-tients received antracycline adjuvant chemotherapy. The recurrence rate, distant metastasis rate and mortality rate between two groups were analyzed. The impact of the two chemotherapy regimens on prognosis of patients in different clinical stages, pathologic types and lymph node stages was further investigated. Results The recur-rence rate, distant metastasis rate and mortality rate were 7.9% vs 13.2%, 21.9% vs 35.9% and 18.0% vs 28.6%in taxanes plus antracycline group and single antracycline group, respectively. The differences were statistically significant (P<0.05). Taxanes plus antracycline adjuvant chemotherapy improved favorably the patients in clini-cal stages II and III, or the patients with a non-special invasive type or lymphatic metastasis, overall survival time and survival rate in comparison with single antracycline drug treatment group. Conclusion Compared with anthracycline regimens, the effect of taxanes combined anthracycline was more prominent in later clinical stage, non-special type invasive breast carcinoma and lymphatic metastasis triple-negative breast cancer pa-tients can improve the prognosis.
